The Benefits of Cardiac Stem Cell Therapy

Cardiac Stem Cell Therapy Benefits

If you are suffering from chronic heart disease and have done everything your cardiologist has asked you to do, you may still be challenged by symptoms that keep you from your daily activities and the things you enjoy doing.

The power of your body’s own natural biology can be harnessed to repair some of the damage caused by coronary artery disease and previous heart attacks. Okyanos Cardiac Cell Therapy is a new, promising option for advanced heart disease patients.

Cardiac Stem Cell Treatment Benefits

In the independent clinical trial known as PRECISE, doctors reintroduced patients’ own fat-derived adult stem cells into the heart tissue, and the results were:

  • Improved oxygen consumption—the heart became more able to take in and utilize oxygen.
  • Reduction of the infarction—the size of the wound sustained during a heart attack.

In simpler terms, the re-introduction of adult stem cells into the heart tissue itself resulted in improvements in patients’ ability to breathe and perform physical activity, both benefits which were seen in patients 6, 12 and 18 months after treatment.

At Okyanos, our adult stem cell treatment protocol is modeled after the PRECISE trial for the purpose of bringing cutting edge research, maximal safety and benefit to our patients.

What does this mean for your quality of life?

When an artery of the heart becomes blocked, the heart muscle struggles to function normally due to the disruption of blood flow. Coronary artery disease is a heart disease in which plaque builds up in the arteries of the heart, causing ischemia (inhibited flow) which gradually damages the heart more and more over time.

Adult Stem Cell Therapy BenefitsSimilarly, a heart attack occurs when blood flow has been severely cut off to the heart because of a more sudden blockage in the arteries. If this loss of blood flow continues, it can lead to death of heart muscle cells. This type of damage is medically known as a myocardial infarction, or heart attack.

The oxygen starvation caused by a heart attack causes the affected zone of heart muscle cells to die or become damaged, developing what is known as an infarction—a wound or area of scar tissue. Further damage can occur in other areas of the heart if blood flow to those areas is also restricted. Hence, the term myocardial infarctionliterally means a death of the heart muscle.

In short, the reason your heart doesn’t function as well after a heart attack or as a result of advanced coronary artery disease, is because lack of blood flow has caused serious damage to the heart muscle.

In the PRECISE trial, the re-introduction of adult stem cells into the heart tissue itself resulted in patients’ ability to better perform physical activity and breathe better, both benefits which were seen in patients 6, 12 and 18 months after treatment.

When your own adipose-derived stem cells are reintroduced into the damaged zones of your heart, we begin to see the formation of new blood vessel growth in the heart tissue. This process supports better heart function and, in turn, a better quality of life.

To learn more, you may contact a Patient Liaison by requesting a free educational consultation or dialing 855.OKYANOS (659.2667).

References

Cytori Therapeutics (2010) Adipose-Derived Regenerative Cells Improve Cardiac Functional Capacity at 18 Months in Chronic Ischemic Heart Disease Patients; Statistically Significant Improvement in MVO2 Reported by Cytori at American Heart Association.

Perin et al (2014) Adipose-Derived Regenerative Cells in Patients with Ischemic Cardiomyopathy: The PRECISE Trial, American Heart Journal, Vol. 168, Number 1.

Adipose-Derived Regenerative Cells Improve Cardiac Functional Capacity at 18 Months in Chronic Ischemic Heart Disease Patients; Statistically Significant Improvement in MVO2 Reported at American Heart Association (2010, November 15) in Marketwire. Retrieved March 9, 2012, from http://www.marketwire.com/press-release/Adipose-Derived-Regenerative-Cells-Improve-Cardiac-Functional-Capacity-18-Months-Chronic-NASDAQ-CYTX-1353581.htm